Illicit drug use and injection practices among drug users on methadone and buprenorphine maintenance treatment in France. 2003

Anne Guichard, and France Lert, and Christine Calderon, and Hind Gaigi, and Olivier Maguet, and Jérôme Soletti, and Jean-Marc Brodeur, and Lucie Richard, and Mike Benigeri, and Maria-Victoria Zunzunegui
French Institute of Health and Medical Research (INSERM U88), Hôpital National de Saint-Maurice, St-Maurice, France. anne.guichard@st-maurice.inserm.fr

OBJECTIVE To evaluate the associations between methadone and high-dose buprenorphine maintenance treatment and illicit drug use and injection among drug users in France. METHODS A cross-sectional study. Data were gathered using a questionnaire administered containing closed-ended questions. METHODS Drug dependence clinics (DDC) and general practitioners' (GPs) offices in three French cities. METHODS Drug users undergoing maintenance treatment with methadone (n = 197) and buprenorphine (n = 142). METHODS Interviews covered the use of illicit drugs (heroin, cocaine or crack) and injection practices (illicit drugs and/or substitution drugs) during the last month, current treatment modalities, socio-demographic and health characteristics. Bivariate analysis and multivariate logistic regressions were conducted. RESULTS Overall, 35.4% of respondents (34.5% in the methadone group, 36.6% in the buprenorphine group, P= 0.69) had used at least one illicit drug, 25.7% reported having injected drugs and 15.3% had injected the substitution drug. Injection was more common among buprenorphine-maintained individuals (40.1%) than among users on methadone (15.2%) (P < 0.01). Multivariate analyses indicate that the type of substitution drug (buprenorphine versus methadone) was not associated with illicit drug use (OR = 1.1; 95% CI = 0.7-1.8). In the buprenorphine group, injection was related independently to social situation, as measured by housing (unstable versus stable housing, OR = 4.3; 95% CI = 1.6-11.5), but this was not the case in the methadone group. The risk of injection increased with buprenorphine dosage (high/low dosage OR = 6.2; 95% CI = 2.0-19.7), but this association was not observed in the methadone group. CONCLUSIONS Further studies comparing the benefits of these two types of treatment should be carried out, taking outcomes such as physical health, mental health and social functioning into consideration.

UI MeSH Term Description Entries
D008297 Male Males
D008691 Methadone A synthetic opioid that is used as the hydrochloride. It is an opioid analgesic that is primarily a mu-opioid agonist. It has actions and uses similar to those of MORPHINE. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1082-3) Amidone,Biodone,Dolophine,Metadol,Metasedin,Methaddict,Methadone Hydrochloride,Methadose,Methex,Phenadone,Phymet,Physeptone,Pinadone,Symoron,Hydrochloride, Methadone
D002047 Buprenorphine A derivative of the opioid alkaloid THEBAINE that is a more potent and longer lasting analgesic than MORPHINE. It appears to act as a partial agonist at mu and kappa opioid receptors and as an antagonist at delta receptors. The lack of delta-agonist activity has been suggested to account for the observation that buprenorphine tolerance may not develop with chronic use. 6029-M,Buprenex,Buprenorphine Hydrochloride,Buprex,Prefin,RX-6029-M,Subutex,Temgesic,Temgésic,6029 M,6029M,Hydrochloride, Buprenorphine,RX 6029 M,RX6029M
D004812 Epidemiologic Methods Research techniques that focus on study designs and data gathering methods in human and animal populations. Epidemiologic Method,Epidemiological Methods,Methods, Epidemiologic,Epidemiological Method,Method, Epidemiologic,Method, Epidemiological,Methods, Epidemiological
D005260 Female Females
D005602 France A country in western Europe bordered by the Atlantic Ocean, the English Channel, the Mediterranean Sea, and the countries of Belgium, Germany, Italy, Spain, Switzerland, the principalities of Andorra and Monaco, and by the duchy of Luxembourg. Its capital is Paris. Corsica,Saint Pierre and Miquelon,Miquelon and Saint Pierre,Miquelon and St. Pierre,St. Pierre and Miquelon
D006798 Housing Living facilities for humans. Family-Patient Lodging,Patient-Family Lodging,Family Patient Lodging,Family-Patient Lodgings,Lodging, Family-Patient,Lodging, Patient-Family,Lodgings, Family-Patient,Lodgings, Patient-Family,Patient Family Lodging,Patient-Family Lodgings
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

Anne Guichard, and France Lert, and Christine Calderon, and Hind Gaigi, and Olivier Maguet, and Jérôme Soletti, and Jean-Marc Brodeur, and Lucie Richard, and Mike Benigeri, and Maria-Victoria Zunzunegui
January 2006, Journal of opioid management,
Anne Guichard, and France Lert, and Christine Calderon, and Hind Gaigi, and Olivier Maguet, and Jérôme Soletti, and Jean-Marc Brodeur, and Lucie Richard, and Mike Benigeri, and Maria-Victoria Zunzunegui
January 1994, Journal of substance abuse treatment,
Anne Guichard, and France Lert, and Christine Calderon, and Hind Gaigi, and Olivier Maguet, and Jérôme Soletti, and Jean-Marc Brodeur, and Lucie Richard, and Mike Benigeri, and Maria-Victoria Zunzunegui
June 2003, Journal of substance abuse treatment,
Anne Guichard, and France Lert, and Christine Calderon, and Hind Gaigi, and Olivier Maguet, and Jérôme Soletti, and Jean-Marc Brodeur, and Lucie Richard, and Mike Benigeri, and Maria-Victoria Zunzunegui
December 2014, Addiction (Abingdon, England),
Anne Guichard, and France Lert, and Christine Calderon, and Hind Gaigi, and Olivier Maguet, and Jérôme Soletti, and Jean-Marc Brodeur, and Lucie Richard, and Mike Benigeri, and Maria-Victoria Zunzunegui
May 2004, Drug and alcohol dependence,
Anne Guichard, and France Lert, and Christine Calderon, and Hind Gaigi, and Olivier Maguet, and Jérôme Soletti, and Jean-Marc Brodeur, and Lucie Richard, and Mike Benigeri, and Maria-Victoria Zunzunegui
January 2019, Substance use & misuse,
Anne Guichard, and France Lert, and Christine Calderon, and Hind Gaigi, and Olivier Maguet, and Jérôme Soletti, and Jean-Marc Brodeur, and Lucie Richard, and Mike Benigeri, and Maria-Victoria Zunzunegui
August 1985, Journal of consulting and clinical psychology,
Anne Guichard, and France Lert, and Christine Calderon, and Hind Gaigi, and Olivier Maguet, and Jérôme Soletti, and Jean-Marc Brodeur, and Lucie Richard, and Mike Benigeri, and Maria-Victoria Zunzunegui
January 2007, The American journal of drug and alcohol abuse,
Anne Guichard, and France Lert, and Christine Calderon, and Hind Gaigi, and Olivier Maguet, and Jérôme Soletti, and Jean-Marc Brodeur, and Lucie Richard, and Mike Benigeri, and Maria-Victoria Zunzunegui
July 2000, Drug and alcohol dependence,
Anne Guichard, and France Lert, and Christine Calderon, and Hind Gaigi, and Olivier Maguet, and Jérôme Soletti, and Jean-Marc Brodeur, and Lucie Richard, and Mike Benigeri, and Maria-Victoria Zunzunegui
January 2013, Journal of addiction medicine,
Copied contents to your clipboard!